Navigation Links
ASAM Approves Prescription Drug Policy
Date:1/26/2012

CHEVY CHASE, Md., Jan. 26, 2012 /PRNewswire-USNewswire/ -- "Prescription drug diversion and the health consequences of prescription drug misuse and abuse should be of primary concern to all physicians," states American Society of Addiction Medicine (ASAM) Acting President, Stuart Gitlow, MD.  "Tens of thousands of Americans are overdosing on prescription pain medication and many of these prescriptions are coming from doctors' offices." 

Chronic pain and addiction are issues faced by patients from all walks of life and in all types of treatment settings.  And, yet, very few physicians are sufficiently educated about the potential psychiatric and addiction consequences of prescribing scheduled medications like opioid analgesics and sedative hypnotics (two of the most commonly misused classes of prescription medication).  The Centers for Disease Control and Prevention reports that the sale of prescription pain drugs has increased by 300% since 1999 and the most recent National Survey on Drug Use and Health (Substance Abuse and Mental Health Administration) reports that nearly 1 in 6 non-medical users of prescription pain killers got the drug through a prescription from a doctor.  Currently, there are no requirements that prescribers prove they are competent to prescribe these potentially lethal drugs. 

"Prescription drug use and overdose death are becoming a public health crisis," says Dr. Gitlow.  "Physicians and patients should understand the risks and benefits of using these powerful drugs and make educated treatment choices."  To that end, ASAM recommends that all health professionals who can prescribe scheduled medications must be included in any educational efforts to improve patient outcomes and public health.  One part of the solution is to mandate prescriber education for all health professionals licensed to prescribe, dispense or administer prescription drugs.  A public health response should also include patient education, training for medical students and residents in safe prescribing practices, pain medicine and addiction medicine, implementation of coordinated state prescription drug monitoring programs, and support for continued research on patterns of manufacture, distribution and sales of psychoactive drugs which have the potential for diversion and misuse. 

To read ASAM's Public Policy Statement on Measures to Counteract Prescription Drug Diversion, Misuse and Dependence, please click here.

The American Society for Addiction Medicine is a professional society representing close to 3,000 physicians dedicated to increasing access and improving quality of addiction treatment, educating physicians and the public, supporting research and prevention, and promoting the appropriate role of physicians in the care of patients with addictions.

Contact: Alexis Geier-Horan
(301) 656-3920 x103
ageier@asam.org
www.asam.org


'/>"/>
SOURCE American Society of Addiction Medicine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):